Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribut...

Full description

Bibliographic Details
Main Authors: Beyrer, J. (Author), Blumenschein, G. (Author), Cui, Z.L (Author), Kim, S. (Author), Lee, H.-Y (Author), Li, X. (Author), Molife, C. (Author), Nagasaka, M. (Author), Stefaniak, V. (Author)
Format: Article
Language:English
Published: Future Medicine Ltd. 2022
Subjects:
Adjustment
Anti-PD-1
Entropy balancing
Immunotherapy
Inverse probability reweighting
Nonsquamous non-small-cell lung cancer
ORIENT-11
Progression-free survival
Sintilimab
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items